The U2AF1$^{S34F}$ mutation induces lineage-specific splicing alterations in myelodysplastic syndromes by Yip, BH et al.
The Journal of Clinical Investigation R E S E A R C H  A R T I C L E
2 2 0 6 jci.org   Volume 127   Number 6   June 2017
Introduction
The myelodysplastic syndromes (MDS) are a heterogeneous 
group of clonal hematopoietic stem cell malignancies character-
ized by ineffective hematopoiesis resulting in peripheral blood 
cytopenias of the myeloid lineage, including anemia and neutro-
penia. Patients with MDS show increasing bone marrow myeloid 
blasts as the disease progresses, and approximately 40% of these 
patients develop acute myeloid leukemia (AML). MDS is as com-
mon as de novo AML, with an incidence of 4 per 100,000 per year 
(1–4). Patients with the more advanced MDS subtypes (refractory 
anemia with excess blasts 1 and 2) have a median overall survival 
of less than 2 years, highlighting the severity of these diseases (1, 
2, 4). The recent finding that splicing factor genes are the most 
commonly mutated genes found in MDS (5, 6) revealed a new leu-
kemogenic pathway involving spliceosomal dysfunction in this 
disorder. Over half of all patients with MDS carry spliceosome 
gene mutations (6, 7), with splicing factor 3b subunit 1 (SF3B1), 
serine and arginine–rich splicing factor 2 (SRSF2), U2 small 
nuclear RNA auxiliary factor 1 (U2AF1), and zinc finger CCCH-
type, RNA-binding motif and serine/arginine rich 2 (ZRSR2) 
being the most frequently mutated splicing factor genes (6). The 
common spliceosome mutations in MDS have differing prog-
nostic impacts (8–10) and to some extent define distinct clinical 
phenotypes (5, 8, 11). While at present there is a lack of extensive 
direct evidence that the alterations in pre-mRNA splicing caused 
by mutations in splicing factors are the main mechanism driving 
the disease in MDS, aberrant splicing of some key downstream 
target genes (e.g., ATP-binding cassette subfamily B member 7 
[ABCB7] and enhancer of zeste 2 polycomb repressive complex 2 
subunit [EZH2]) linked to splicing factor gene (SF3B1 and SRSF2) 
mutations has been shown to be associated with certain MDS dis-
ease aspects and phenotypes (12, 13).
Mutations of the splicing factor–encoding gene U2AF1 are frequent in the myelodysplastic syndromes (MDS), a myeloid 
malignancy, and other cancers. Patients with MDS suffer from peripheral blood cytopenias, including anemia, and an 
increasing percentage of bone marrow myeloblasts. We studied the impact of the common U2AF1S34F mutation on cellular 
function and mRNA splicing in the main cell lineages affected in MDS. We demonstrated that U2AF1S34F expression in 
human hematopoietic progenitors impairs erythroid differentiation and skews granulomonocytic differentiation toward 
granulocytes. RNA sequencing of erythroid and granulomonocytic colonies revealed that U2AF1S34F induced a higher number 
of cassette exon splicing events in granulomonocytic cells than in erythroid cells. U2AF1S34F altered mRNA splicing of many 
transcripts that were expressed in both cell types in a lineage-specific manner. In hematopoietic progenitors, the introduction 
of isoform changes identified in the U2AF1S34F target genes H2AFY, encoding an H2A histone variant, and STRAP, encoding 
serine/threonine kinase receptor–associated protein, recapitulated phenotypes associated with U2AF1S34F expression in 
erythroid and granulomonocytic cells, suggesting a causal link. Furthermore, we showed that isoform modulation of H2AFY 
and STRAP rescues the erythroid differentiation defect in U2AF1S34F MDS cells, suggesting that splicing modulators could be 
used therapeutically. These data have critical implications for understanding MDS phenotypic heterogeneity and support the 
development of therapies targeting splicing abnormalities.
The U2AF1S34F mutation induces lineage-specific 
splicing alterations in myelodysplastic syndromes
Bon Ham Yip,1 Violetta Steeples,1 Emmanouela Repapi,2 Richard N. Armstrong,1 Miriam Llorian,3 Swagata Roy,1  
Jacqueline Shaw,1 Hamid Dolatshad,1 Stephen Taylor,2 Amit Verma,4 Matthias Bartenstein,4 Paresh Vyas,5 Nicholas C.P. Cross,6 
Luca Malcovati,7 Mario Cazzola,7 Eva Hellström-Lindberg,8 Seishi Ogawa,9 Christopher W.J. Smith,3 Andrea Pellagatti,1  
and Jacqueline Boultwood1
1Bloodwise Molecular Haematology Unit, Nuffield Division of Clinical Laboratory Sciences, Radcliffe Department of Medicine, University of Oxford, and BRC Blood Theme, National Institute for Health 
Research (NIHR) Oxford Biomedical Centre, Oxford University Hospital, Oxford, United Kingdom. 2The Computational Biology Research Group, Weatherall Institute of Molecular Medicine, University of 
Oxford, Oxford, United Kingdom. 3Department of Biochemistry, Downing Site, University of Cambridge, Cambridge, United Kingdom. 4Albert Einstein College of Medicine, Bronx, New York, USA. 5Medical 
Research Council, Molecular Hematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, and Department of Hematology, Oxford University Hospital National Health Service Trust, 
Oxford, United Kingdom. 6Faculty of Medicine, University of Southampton, Southampton, and National Genetics Reference Laboratory (Wessex), Salisbury, United Kingdom. 7Fondazione IRCCS Policlinico 
San Matteo and University of Pavia, Pavia, Italy. 8Center for Hematology and Regenerative Medicine, Karolinska University Hospital Huddinge, Stockholm, Sweden. 9Department of Pathology and Tumor 
Biology, Kyoto University, Kyoto, Japan.
Authorship note: A. Pellagatti and J. Boultwood contributed equally to this work.
Conflict of interest: The authors have declared that no conflict of interest exists
License: This work is licensed under the Creative Commons Attribution 4.0 International 
License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Submitted: October 21, 2016; Accepted: February 21, 2017.
Reference information: J Clin Invest. 2017;127(6):2206–2221. 
https://doi.org/10.1172/JCI91363.
The Journal of Clinical Investigation   R E S E A R C H  A R T I C L E
2 2 0 7jci.org   Volume 127   Number 6   June 2017
https://doi.org/10.1172/JCI91363DS1). The gene expression lev-
els of U2AF1S34F and U2AF1WT compared with levels in the empty 
vector (EV) control were confirmed by real-time quantitative PCR 
(qRT-PCR) in transduced cells harvested on day 11 (Supplemen-
tal Figure 1B). The expression of U2AF1S34F in transduced cells 
was confirmed by Sanger sequencing (Supplemental Figure 1C). 
Expression of U2AF1S34F and U2AF1WT protein in transduced cells 
harvested on day 11 was detected using anti-FLAG and anti-U2AF1 
antibodies (Figure 1A and Figure 2A). Overexpression of exoge-
nous U2AF1S34F and U2AF1WT protein, driven by retroviral vectors 
(anti-FLAG antibody), resulted in a modest increase (approxi-
mately 1.5- to 2.0-fold increase, i.e., not a large excess compared 
with the levels observed in the EV control) of total U2AF1 pro-
tein levels (anti-U2AF1 antibody) in U2AF1S34F- and U2AF1WT- 
transduced cells throughout erythroid and granulomonocytic dif-
ferentiation (Supplemental Figure 1D).
U2AF1S34F impairs erythroid differentiation. To investigate 
the effect of U2AF1S34F on erythroid differentiation, transduced 
hematopoietic progenitors were cultured using a method devel-
oped to study the generation of erythroblasts (27), and eryth-
roblasts were harvested on day 11 and day 14 of culture for flow 
cytometric measurement of the erythroid cell-surface markers 
CD71 and CD235a (Figure 1, B–E). We observed a significant 
increase in the CD71–CD235a– nonerythroid cell population (Fig-
ure 1B) and a significant decrease in the CD71+CD235a+ inter-
mediate erythroid cell population (Figure 1C) in U2AF1S34F eryth-
roblasts on day 11 compared with the U2AF1WT and EV controls. 
We observed a decrease in the late CD71–CD235a+ erythroid cell 
population in U2AF1S34F erythroblasts on day 14 compared with 
the U2AF1WT and EV controls (Figure 1, D and E). Examination 
of erythroblasts on day 14 revealed that U2AF1S34F erythroblasts 
had defective hemoglobinization compared with the U2AF1WT 
and EV controls (Figure 1F). To further characterize the effect 
of U2AF1S34F on erythroid differentiation, we performed colony- 
forming cell assays and found that U2AF1S34F-transduced 
progenitors produced a significantly lower number of burst- 
forming unit–erythroid (BFU-E) colonies than did the U2AF1WT 
and EV controls after 14 days in culture (Figure 1G). Morphologi-
cal examination of BFU-E colonies revealed that U2AF1S34F inhib-
ited colony growth, resulting in smaller colonies, and impaired 
hemoglobinization (Figure 1H). Transduced erythroblasts under-
went Geneticin selection on day 3 following retroviral transduc-
tion. The cells were harvested on day 8 for cell growth assays 
until day 14 in culture (Figure 1I). U2AF1S34F erythroblasts showed 
impaired cell growth compared with the U2AF1WT and EV con-
trols (Figure 1I). We found no change in cell-cycle pattern among 
the samples (Supplemental Figure 1E), but observed a significant 
increase in apoptosis in U2AF1S34F erythroblasts harvested on day 
11 compared with the U2AF1WT and EV controls (Figure 1J). These 
results indicate that U2AF1S34F impaired cell growth and increased 
apoptosis in erythroblasts and led to impaired differentiation.
U2AF1S34F skews granulomonocytic differentiation toward granu-
locytes. To investigate the effects of U2AF1S34F on granulomonocytic 
differentiation, transduced hematopoietic progenitors were cul-
tured under granulomonocytic differentiating conditions (28), and 
granulomonocytic cells were harvested on day 11 and day 14 of cul-
ture for flow cytometric measurement of the myeloid cell-surface 
Pre-mRNA splicing involves the excision of intronic sequenc-
es from pre-mRNAs (14) and is performed by the spliceosome, 
a complex of 5 small nuclear ribonucleoproteins (snRNPs) and 
other supplementary proteins. U2AF1 (also known as U2AF35) is 
a U2 auxiliary factor that forms a heterodimer with U2AF2 (also 
known as U2AF65) for the recognition of the 3′ splice site and sub-
sequent recruitment of U2 snRNPs during pre-mRNA splicing (15, 
16). Mutations in U2AF1 have been found in approximately 11% of 
patients with MDS (6, 17), making U2AF1 one of the most common-
ly mutated genes in this disease. Mutations in U2AF1 also occur in 
the closely related condition AML at a frequency of approximately 
4% (18), as well as in lung adenocarcinoma and other cancers (18, 
19). U2AF1 mutations are associated with a worse overall surviv-
al in MDS patients and a higher risk of transformation to AML (11, 
20, 21). U2AF1 mutations almost exclusively occur in 2 highly con-
served amino acid positions, S34 and Q157, within the 2 zinc finger 
domains of the protein (6). There is clear evidence in yeast show-
ing that the zinc finger domains in U2AF1 recognize RNA (6). The 
high percentage of sequence identity in the zinc finger domains 
between yeast and human U2AF1 (6) suggests that the zinc finger 
domains in human U2AF1 are also RNA binding (22). The presence 
of missense mutational hotspots and the absence of nonsense/
frameshift mutations suggest that U2AF1 mutations are gain-of-
function or change-of-function/neomorphic mutations (6).
Abnormal RNA splicing, with cassette exon splicing being the 
most frequent type of event, has been reported in bone marrow 
samples from U2AF1-mutant MDS and AML patients (18, 23, 24). 
Several studies demonstrated that differentially spliced exons 
exhibited different consensus nucleotides at the –3 and +1 posi-
tions flanking the AG dinucleotide of the 3′ splice site (18, 23–25). 
Thymidine (uridine) was observed less frequently than cytosine at 
the –3 position of the 3′ splice site in the U2AF1 S34F mutant com-
pared with U2AF1 WT samples (18, 23, 25).
Recently, Shirai et al. generated a doxycycline-inducible trans-
genic mouse model of U2AF1 S34F mutation displaying some phe-
notypes that are closely associated with MDS (26). This transgenic 
murine model sheds light on the role of this mutation in altering 
hematopoesis and pre-mRNA splicing in the mouse (26). An inves-
tigation of the lineage-specific effect of U2AF1 S34F mutation on 
human hematopoiesis could provide new insights into the molec-
ular pathogenesis of U2AF1-mutant MDS and illuminate how this 
mutation impacts the MDS phenotype.
Here, we demonstrate that the U2AF1 S34F mutation exhibits 
lineage specificity in altering pre-mRNA splicing of downstream 
target genes, resulting in different phenotypes in the different 
myeloid lineages that are involved in MDS.
Results
Expression of U2AF1S34F in hematopoietic progenitors. To study the 
impact of the U2AF1 S34F mutation on erythroid and granulo-
monocytic differentiation, we first overexpressed the U2AF1 S34F 
mutant (U2AF1S34F) and U2AF1 WT (U2AF1WT) in primary human 
bone marrow CD34+ progenitor cells by retroviral transduction. 
Transduced progenitor cells were then cultured under erythroid 
or granulomonocytic conditions for differentiation into erythroid 
and granulomonocytic cells, respectively (Supplemental Fig-
ure 1A; supplemental material available online with this article; 
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arrest in granulomonocytic cells compared with the U2AF1WT and 
EV controls (Figure 2E). These data demonstrate impaired growth 
and differentiation of U2AF1S34F granulomonocytic cells.
We also evaluated granulomonocytic differentiation on 
day 20 of culture and observed a significant decrease in the 
CD11b+ cell population in U2AF1S34F granulomonocytic cells 
compared with U2AF1WT and EV controls (Figure 2F). Moreover, 
we observed a significant decrease in the CD14+ monocytic cell 
population and a concomitant significant increase in the CD15+ 
granulocytic cell population in U2AF1S34F granulomonocytic cells 
compared with the U2AF1WT and EV controls, indicating a skew-
ing effect of U2AF1S34F on granulomonocytic differentiation (Fig-
ure 2, G–I). To confirm this phenotype, granulomonocytic cells 
were stained with May-Grünwald and Giemsa for morphological 
examination (Figure 2, J and K). Consistent with the flow cyto-
metric data (Figure 2, G –I), we observed an expansion of the 
granulocyte population, specifically eosinophils, in U2AF1S34F 
markers CD11b, CD14, and CD15. CD11b is a myeloid cell-surface 
marker expressed on granulocytes, monocytes, and macrophages 
(29). CD14 and CD15 are expressed predominantly on monocytes 
and granulocytes, respectively, and were used as lineage discrimina-
tors between monocytic and granulocytic cell populations (30). Giv-
en the signal intensity of forward scatter (as a measure of cell size), 
U2AF1S34F granulomonocytic cells were larger than the U2AF1WT 
and EV controls (Figure 2B and Supplemental Figure 1F). We 
observed a significant decrease in the CD11b+ cell population in 
U2AF1S34F granulomonocytic cells compared with that seen in the 
U2AF1WT and EV controls on days 11 and 14 (Figure 2C). Howev-
er, no difference in CD14+ or CD15+ cell populations was observed 
among samples at these 2 time points (data not shown). U2AF1S34F 
granulomonocytic cells showed impaired cell growth compared 
with the U2AF1WT and EV controls (Figure 2D). We observed no dif-
ference in apoptosis in U2AF1S34F granulomonocytic cells (Supple-
mental Figure 1G), however, U2AF1S34F triggered a G2/M cell-cycle 
Figure 1. Expression of U2AF1S34F impairs erythroid differentiation. (A) Western blots showing expression levels of U2AF1S34F and U2AF1WT protein in 
transduced erythroid cells harvested on day 11. An anti-U2AF1 antibody was used to measure total U2AF1 protein, while an anti-FLAG antibody was used 
to measure the exogenous U2AF1S34F or U2AF1WT protein produced by the vector. (B–D) Erythroid differentiation was measured by flow cytometry using 
expression of CD71 and CD235a cell-surface markers. (B) Nonerythroid (CD71–CD235a–) and (C) intermediate erythroid (CD71+CD235a+) cell populations on 
day 11 of culture and (D) late erythroid (CD71–CD235a+) cell population on day 14 of culture. (E) Representative flow cytometric plots showing impaired 
erythroid differentiation on day 14 (n = 8). (F) Image of erythroid cell pellets on day 14 of culture for visual determination of hemoglobinization (n = 8). 
(G) Number of BFU-E colonies obtained from hematopoietic CD34+ progenitors transduced with EV, U2AF1WT, or U2AF1S34F after 14 days in methylcellulose 
(colony-forming cell assays). (H) Representative images of BFU-E colonies produced from hematopoietic CD34+ progenitors transduced with EV, U2AF1WT, 
or U2AF1S34F, respectively (n = 7). Scale bars: 100 μm. (I) Cell counts for U2AF1S34F erythroid cells from day 8 to day 14 of culture compared with counts for EV 
and U2AF1WT controls. (J) Apoptosis as measured by annexin V staining and flow cytometry in erythroblasts harvested on day 11 of culture. Results shown 
in panels B–D were obtained from 8 independent experiments, those shown in panels G and I were obtained from 7 independent experiments, and results 
shown in panel J were obtained from 6 independent experiments. Data represent the mean ± SEM. P values in panels B–D, G, and J were calculated by 
repeated-measures 1-way ANOVA with Tukey’s post-hoc test. P values in panel I were calculated by 2-way ANOVA with Bonferroni’s post test.  
*P < 0.05, **P < 0.01, and ***P < 0.001.
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the myeloid or erythroid lineage, we performed RNA sequencing 
(RNA-seq) on individual erythroid and granulomonocytic colo-
nies formed in colony-forming cell assays by bone marrow CD34+ 
cells transduced with U2AF1S34F, U2AF1WT, or EV control. The 
U2AF1S34F variant allele frequency was greater than 80% in eryth-
roid and granulomonocytic colonies expressing the U2AF1 S34F 
mutation, as measured by pyrosequencing (Figure 3A). Replicate 
MATS (rMATS), a computational tool designed for the detection of 
differential alternative splicing from replicate RNA-seq data (31), 
was used for RNA-seq data analysis. A total of 506 splicing events 
granulomonocytic cells compared with U2AF1WT and EV controls 
(Figure 2, J and K). Furthermore, U2AF1S34F-transduced progen-
itors produced a significantly lower number of CFU-M colonies 
and a significantly higher number of CFU-G colonies in myeloid 
colony–forming cell assays (Figure 2L). Our results indicate that 
U2AF1S34F perturbs granulomonocytic cells by skewing their dif-
ferentiation from monocytes toward granulocytes.
U2AF1S34F differentially alters splicing in erythroid and granulo-
monocytic colonies. In order to investigate the effects of the pres-
ence of U2AF1S34F on pre-mRNA splicing in cells committed toward 
Figure 2. Expression of U2AF1S34F skews granulomonocytic differentiation toward granulocytes. (A) Expression levels of U2AF1S34F and U2AF1WT protein in 
transduced granulomonocytic cells on day 11. Anti-U2AF1 and anti-FLAG antibodies were used to measure total U2AF1 protein and exogenous U2AF1S34F or 
U2AF1WT protein produced by the vector, respectively. (B) Median fluorescence intensity (MFI) of forward scatter (an indication of cell size) of granulomono-
cytic cells on days 11 and 14. (C) Percentage of CD11b+ cells in granulomonocytic cultures on days 11 and 14. (D) Cell counts for U2AF1S34F granulomonocytic 
cells from day 8 (the day when Geneticin selection was complete) to day 14 compared with EV and U2AF1WT controls. (E) Cell-cycle analysis of granulomono-
cytic cells on day 11. (F) Percentage of CD11b+ cells in granulomonocytic cultures on day 20. (G and H) Percentages of (G) CD14+CD15– monocytic cells and (H) 
CD14–CD15+ granulocytic cells in granulomonocytic cultures on day 20. (I) Representative flow cytometric plots on day 20 (n = 7). (J) Representative images of 
May-Grünwald-Giemsa–stained granulomonocytic cells on day 20 (n = 7). The red arrows indicate eosinophils. Scale bars: 25 μm. (K) Percentage of eosino-
phils per 100 cells on day 20. (L) Number of CFU granulocytes-macrophages (CFU-GM), CFU granulocytes (CFU-G), and CFU macrophages (CFU-M) obtained 
from hematopoietic CD34+ progenitors transduced with EV, U2AF1WT, or U2AF1S34F after 14 days in methylcellulose. Results shown in panels B–H, K, and L 
were obtained from 6, 8, 7, 6, 7, 7, 7, 6, and 7 independent experiments, respectively. Data represent the mean ± SEM. P values in panels B, C, E–H, K and L 
were calculated by repeated-measures 1-way ANOVA with Tukey’s post-hoc test. P values in panel D were calculated by 2-way ANOVA with Bonferroni’s post 
test. *P < 0.05, **P < 0.01, and ***P < 0.001. 
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U2AF1S34F colonies in both comparisons with the U2AF1WT and EV 
controls (Figure 3, B and C). This increase in the number of cassette 
exon events accounts for the higher number of total aberrant splic-
ing events associated with granulomonocytic U2AF1S34F colonies 
compared with erythroid U2AF1S34F colonies (Figure 3, B and C).
We investigated the properties of misregulated cassette 
exons and cassette exons that were unaffected by U2AF1S34F 
compared with U2AF1WT (Figure 3D and Supplemental Figure 
2). Cassette exons that were more included or that were unreg-
ulated showed the normal preference for CAG 3′ splice sites. In 
contrast, exons that were more skipped in response to U2AF1S34F 
showed a strong enrichment for TAG 3′ splice sites (Figure 3D, 
position 33 on the sequence logos), as observed previously (18, 23, 
(347 genes) and 439 splicing events (300 genes) were identified 
in U2AF1S34F erythroid colonies compared with the U2AF1WT and 
EV controls, respectively (see Supplemental data file 1). A total of 
643 splicing events (447 genes) and 676 splicing events (474 genes) 
were identified in U2AF1S34F granulomonocytic colonies compared 
with the U2AF1WT and EV controls, respectively (see Supplemen-
tal data file 1). Alteration in cassette exon splicing (i.e., exons that 
are either included or spliced out, showing increased or decreased 
inclusion levels, respectively) was the most common type of aber-
rant splicing event induced by U2AF1S34F in both erythroid and 
granulomonocytic colonies (Figure 3, B and C). We observed a 
significantly higher number of regulated cassette exon events in 
granulomonocytic U2AF1S34F colonies compared with erythroid 
Figure 3. U2AF1S34F differentially alters splicing of target genes in erythroid and granulomonocytic colonies. (A) Quantification of U2AF1 WT (TCT) and 
S34F mutant (TTT) mRNA in erythroid and granulomonocytic colonies, determined by pyrosequencing. (B and C) Aberrant splicing events associated with 
U2AF1S34F, including breakdown by event type, in erythroid and granulomonocytic colonies for (B) U2AF1S34F versus EV and (C) U2AF1S34F versus U2AF1WT. (D) 
Sequence logos for 3′ splice sites of cassette exons that were unaffected (top row), more included (middle row), or more skipped (bottom row) in response 
to U2AF1S34F compared with U2AF1WT. (E) Distribution of exon inclusion and skipping events within the total number of regulated cassette exon events 
in the comparison of U2AF1S34F versus U2AF1WT in erythroid and granulomonocytic colonies. (F) Venn diagram showing the overlap among the genes that 
contained aberrant splicing events induced by U2AF1S34F in erythroid and granulomonocytic colonies in our study. (G–J) Venn diagrams showing the overlap 
among the genes that contained aberrant splicing events induced by U2AF1S34F in different RNA-seq data sets: (G) transgenic mouse CMPs expressing 
U2AF1S34F and erythroid colonies and granulomonocytic colonies in our study; (H) TCGA AML patient samples with U2AF1 S34 mutations and erythroid col-
onies and granulomonocytic colonies in our study; (I) U2AF1S34F MDS CD34+ bone marrow cells (versus MDS cases without splicing factor gene mutations) 
and erythroid colonies and granulomonocytic colonies in our study; and (J) U2AF1S34F MDS CD34+ bone marrow cells (versus healthy controls) and erythroid 
colonies and granulomonocytic colonies in our study. Results in panel A are shown as the mean ± SEM and were obtained from 3 independent experi-
ments. P values in panel B and C were calculated by Fisher’s exact test with Bonferroni’s correction. *P < 0.05 and **P < 0.01. A3SS, alternative 3′ splice 
site; A5SS, alternative 5′ splice site; MXE, mutually exclusive exon; RI, retained intron; SE, skipped (cassette) exon.
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24, 26). These exons also had significantly weaker 5′ splice sites 
than did the U2AF1S34F unregulated exons (Supplemental Figure 
2). Their 3′ splice sites were also weaker than those in unregulat-
ed exons (erythroid only), while their branch point strengths did 
not differ significantly. While we could readily detect differences 
between exons that were more included or skipped in response 
to U2AF1S34F, we observed no differences between the properties 
of exons regulated in erythroid or 
granolumonocytic cells. However, 
we found that the majority of regu-
lated cassette exons (U2AF1S34F vs. 
U2AF1WT) were more skipped in 
erythroid cells (60% more skipped), 
while in granulomonocytic cells only 
45% were more skipped (Figure 3E).
The number of genes showing 
significant aberrant splicing events in 
both comparisons of U2AF1S34F with 
EV and U2AF1S34F with U2AF1WT were 
112 in erythroid colonies and 217 in 
granulomonocytic colonies (Figure 
3F and Supplemental data file 2). A 
total of 92 genes showed aberrant 
splicing events in erythroid colonies 
only and 197 genes in granulomono-
cytic colonies only (Figure 3F and 
Supplemental data file 2). The large 
majority (≥95%) of these genes that 
were aberrantly spliced in either the 
erythroid or granulomonocytic lin-
eage only were also expressed in the 
other lineage (Supplemental Figure 
3A). Twenty genes were common in 
the lists of aberrantly spliced genes 
in erythroid and granulomonocytic 
U2AF1S34F colonies (Figure 3F and 
Supplemental data file 2). For the 
genes that were differentially spliced 
in the erythroid lineage, we found 
that the distribution of their expres-
sion levels (log2 reads per kilobase per 
million [RPKM]) was comparable in 
the erythroid and granulomonocytic 
lineages. Likewise, for the genes that 
were differentially spliced in the gran-
ulomonocytic lineage, we found that 
the distribution of their expression 
levels (log2 RPKM) was comparable 
in the erythroid and granulomono-
cytic lineages (Supplemental Figure 
3B). The limited overlap of aberrantly 
spliced genes between erythroid and 
granulomonocytic colonies suggests 
that the splicing of different sets of 
genes was altered in the erythroid 
and granulomonocytic lineages. We 
performed gene ontology analysis on 
the lists of significant genes showing aberrant splicing events iden-
tified by the rMATS pipeline using GOseq (Bioconductor; http://
bioconductor.org/packages/release/bioc/html/goseq.html). The 
significant main ontology themes for the comparison of erythroid 
U2AF1S34F colonies with EV and/or U2AF1WT are related to heme 
processing and mRNA processing (see Supplemental data files 3 
and 4). Taken together, these data indicate that U2AF1S34F alters tar-
Figure 4. Confirmation of lineage-specific splicing alterations in U2AF1S34F erythroid and granulomono-
cytic cells. (A) Genes of interest (H2AFY and STRAP) that exhibited differential aberrant splicing between 
U2AF1S34F erythroid and granulomonocytic colonies. (B and C) Mutually exclusive exons in H2AFY measured by 
(B) isoform-specific qRT-PCR and confirmed by (C) RT-PCR and gel electrophoresis. (D and E) Exon skipping 
in STRAP measured by (D) isoform-specific qRT-PCR and confirmed by (E) RT-PCR and gel electrophoresis. In 
panels B and D, sashimi plots illustrate RNA-seq results for H2AFY and STRAP in erythroid and granulomono-
cytic colonies. For each gene, the region affected by aberrant splicing is shown, and the aberrant splicing event 
is highlighted in gray. In panel D, the qRT-PCR was specific for the long STRAP isoform, as it was not possible 
to design a qRT-PCR specific for the short isoform (as there are no unique exons that are specific for the short 
isoform). The decrease in expression levels of the long STRAP isoform observed in U2AF1S34F erythroid cells is 
due to the aberrant splicing, which removes exon 2 from the long isoform, resulting in the generation of the 
short isoform and a concomitant depletion of the long isoform. Expression of the isoform associated with 
aberrant splicing by U2AF1S34F in transduced cells was measured by isoform-specific qRT-PCR relative to  
U2AF1WT and EV controls (red bars: erythroid cells; blue bars: granulomonocytic cells). In panels C and E, 
quantification of altered splicing events in gel was performed using ImageJ. Results for each bar graph were 
obtained from 5 independent experiments in panels B–E. Data represent the mean ± SEM. P values in panels 
B–E were calculated by repeated-measures 1-way ANOVA with Tukey’s post-hoc test. *P < 0.05 and **P < 0.01.
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get genes in a lineage-specific manner, driving different phenotypes 
in different myeloid lineages.
To identify common aberrantly spliced genes associated 
with U2AF1 mutations, we performed a comparison of our RNA-
seq data on U2AF1S34F erythroid and granulomonocytic cells with 
RNA-seq data from other studies, including common myeloid 
progenitors (CMPs) from a U2AF1S34F-transgenic mouse (26) and 
AML patient samples with U2AF1 S34 mutations (23) (Figure 3, 
G and H, and Supplemental data files 5 and 6). Approximately 
10% and 30% of the aberrantly spliced genes in our RNA-seq 
data set on erythroid and granulomonocytic colonies were also 
present in the studies of mouse CMPs and AML patient samples, 
respectively (Figure 3, G and H, and Supplemental data files 5 
and 6). The genes that are shared across data sets represent 
important targets of U2AF1S34F.
Moreover, we performed RNA-seq on bone marrow CD34+ cells 
from 2 patients with MDS with the U2AF1S34F mutation, 4 patients 
with MDS without known mutations in splicing factor genes, and 5 
healthy controls. We compared the lists of aberrantly spliced genes 
identified by rMATS in the comparison of U2AF1S34F MDS cases versus 
MDS cases without splicing factor gene mutations and versus healthy 
controls, with the lists of aberrantly spliced genes we identified in 
Figure 5. Knockdown of H2AFY isoform 1.1 perturbs erythroid and granulomonocytic differentiation. (A and B) Expression levels of H2AFY (A) isoform 1.1 
and (B) isoform 1.2 were determined using isoform-specific qRT-PCR in erythroid cells with H2AFY isoform 1.1 knockdown. (C) Images of erythroid cell pellets 
on day 14 of culture for visual determination of hemoglobinization (n = 6). (D and E) Erythroid differentiation measured by expression of CD71 and CD235a 
cell-surface markers using flow cytometry. (D) Intermediate erythroid (CD71+CD235a+) cell population on day 11 of culture and (E) late erythroid (CD71–CD235a+) 
cell population on day 14 of culture. (F) Number of BFU-E obtained from hematopoietic CD34+ progenitors with H2AFY isoform 1.1 knockdown after 14 days 
in methylcellulose (colony-forming cell assays). (G and H) Expression levels of H2AFY (G) isoform 1.1 and (H) isoform 1.2 determined using isoform-specific 
qRT-PCR in granulomonocytic cells with H2AFY isoform 1.1 knockdown. (I) Percentage of CD14+CD15+ cells in granulomonocytic cultures on day 20 of culture. (J) 
Representative flow cytometric contour plots showing expression of CD14 and CD15 on day 20 of culture (n = 8). (K) Representative images of May-Grünwald- 
Giemsa–stained granulomonocytic cells on day 20 of culture (n = 8). The red arrows indicate eosinophils. Scale bars: 25 μm. Results in each bar graph were 
obtained from 6 independent experiments for panels A, B, and D–H, and from 8 independent experiments for panel I. Data represent the mean ± SEM. P 
values in panels A, B, and D–I were calculated by repeated-measures 1-way ANOVA with Tukey’s post-hoc test. *P < 0.05, **P < 0.01, and ***P < 0.001. Scr, 
scramble; sh3, shRNA 3; sh4, shRNA 4.
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genes in U2AF1S34F erythroid and granulomonocytic colonies 
for confirmation of the splicing abnormality identified using 
rMATS. The genes were chosen on the basis of the following cri-
teria: abnormal splicing identified in our study and also in the 
U2AF1S34F-transgenic mouse CMPs and/or The Cancer Genome 
Atlas (TCGA) AML patient samples with U2AF1 S34 mutations (18, 
23, 26); known biological function (particularly regarding hemato-
poiesis); and previously described involvement in tumorigenesis. 
We selected the H2A histone family member Y (H2AFY); serine/
threonine kinase receptor–associated protein (STRAP); SWI/
SNF-related, matrix associated, actin-dependent regulator of 
chromatin, subfamily a, member 5 (SMARCA5); integrin subunit 
β 3–binding protein (ITGB3BP); and ATR serine/threonine kinase 
(ATR) genes for confirmation of the mutant U2AF1-induced splice 
isoform changes identified by RNA-seq in these 5 genes using 
qRT-PCR and RT-PCR and gel electrophoresis.
U2AF1S34F-transduced erythroid and granulomonocytic colonies. We 
found that approximately 40% of the aberrantly spliced genes iden-
tified in U2AF1S34F-transduced erythroid and granulomonocytic colo-
nies, respectively, were also present in the lists of aberrantly spliced 
genes in the comparisons of U2AF1S34F MDS cases versus MDS cases 
without splicing factor gene mutations and versus healthy controls 
(Figure 3, I and J, and Supplemental data files 1, 7, and 8).
The differences in the number of differentially spliced 
target genes identified in U2AF1S34F-transduced erythroid and 
granulomonocytic colonies in our study and the number of 
differentially spliced target genes identified in the other data 
sets mentioned above are likely due to differences in the RNA- 
seq analysis pipeline and/or filtering cutoff values as well as the 
cell type analyzed.
Confirmation of splicing alterations in U2AF1S34F erythroid and 
granulomonocytic cells. We selected several aberrantly spliced 
Figure 6. Knockdown of STRAP impairs erythroid differentiation, and overexpression of ITGB3BP is dispensable for granulomonocytic differentiation. 
(A) Expression levels of STRAP determined using qRT-PCR in erythroid cells with STRAP knockdown. (B) Cell-cycle analysis of erythroid cells on day 11 
of culture. (C) Images of erythroid cell pellets on day 14 of culture for visual determination of hemoglobinization (n = 6). (D) Percentage of late erythroid 
(CD71–CD235a+) cells on day 14 of culture. (E) Number of BFU-E obtained from hematopoietic CD34+ progenitors with STRAP knockdown after 14 days in 
methylcellulose (colony-forming cell assays). (F) Western blots showing the expression levels of the ITGB3BP protein in granulomonocytic cells with ITGB3BP 
overexpression. (G) Cell-cycle analysis of granulomonocytic cells on day 11 of culture. (H) Percentage of CD14+ cells in granulomonocytic cultures on day 20 of 
culture. (I) Percentage of CD15+ cells in granulomonocytic cultures on day 20 of culture. (J) Representative flow cytometric contour plots (from 6 independent 
experiments) showing expression of CD14 and CD15 on day 20 of culture. (K) Representative images of May-Grünwald-Giemsa–stained granulomonocytic 
cells on day 20 of culture (n = 6). The red arrows indicate eosinophils. Scale bars: 25 μm. Results in each bar graph in panels A, B, D, E, and G–I were obtained 
from 6 independent experiments. Data represent the mean ± SEM. P values in panels A, B, D, and E were calculated by repeated-measures 1-way ANOVA 
with Tukey’s post-hoc test. P values in panels H and I were calculated by a paired, 2-tailed t test. *P < 0.05, **P < 0.01, and ***P < 0.001.
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4C) in U2AF1S34F cells compared with the U2AF1WT and EV controls 
occurred preferentially in erythroid cells. In contrast, inclusion of 
exon 2 of ITGB3BP and inclusion of exon 47 of ATR were associ-
ated with U2AF1S34F granulomonocytic cells (Supplemental Figure 
4, B and D). To confirm these splicing alterations, we performed 
isoform-specific qRT-PCR as well as RT-PCR and gel electropho-
resis to measure the isoform changes associated with U2AF1S34F in 
transduced erythroid and granulomonocytic cells, and all splicing 
alterations were concordant with the RNA-seq data (Figure 4, B 
and D, and Supplemental Figure 4, B–D). Moreover, the full-length 
isoforms and the aberrant splice junctions of the selected genes 
(H2AFY and STRAP) were all confirmed by Sanger sequencing 
We identified a mutually exclusive exon splicing alteration in 
H2AFY in both U2AF1S34F erythroid and granulomonocytic colo-
nies (Figure 4, A–C). Decreased usage of exon 6b (which is mutu-
ally exclusive to exon 6a) in the H2AFY gene was observed in both 
U2AF1S34F erythroid and granulomonocytic colonies compared with 
the corresponding U2AF1WT and EV controls (Figure 4, B and C). 
We observed aberrant splicing of STRAP and SMARCA5 in cells of 
the erythroid lineage only (Figure 4, A, D, and E, and Supplemental 
Figure 4, A and C), while splicing alterations of ITGB3BP and ATR 
were found only in granulomonocytic cells (Supplemental Figure 
4, A, B, and D). Increased skipping of exon 2 of STRAP (Figure 4, D 
and E) and skipping of exon 14 of SMARCA5 (Supplemental Figure 
Figure 7. Effects of H2AFY isoform 1.1 and STRAP long isoform overexpression on erythroid and granulomonocytic differentiation in hematopoietic 
progenitors from U2AF1S34F MDS patients. (A) H2AFY isoform 1.1 ratio in U2AF1S34F MDS–differentiated erythroblasts and granulomonocytic cells (day 7 
in culture) compared with that in healthy controls (HC). Arrowheads in blot indicate H2AFY isoform 1.1. (B) STRAP short isoform ratio in U2AF1S34F MDS–
differentiated erythroblasts (day 7 in culture) compared with healthy controls. Arrowheads in blot indicate the STRAP short isoform. (C–E) Impaired 
erythropoiesis and skewed differentiation toward granulocytes in U2AF1S34F MDS hematopoietic progenitors compared with healthy controls. (C) Late 
erythroid (CD71–CD235a+) cell population on day 14 of culture and (D) monocytic (CD14+CD15–) and (E) granulocytic (CD14–CD15+) cell populations on day 20 of 
culture were measured by flow cytometry. (F and G) Overexpression of (F) H2AFY isoform 1.1 and (G) STRAP long isoform in U2AF1S34F MDS hematopoietic 
progenitors differentiating toward erythroid and granulomonocytic lineages. Arrowheads in blots indicate H2AFY isoform 1.1 or the STRAP short isoform. 
(H–K) Effects of H2AFY isoform 1.1 and STRAP long isoform overexpression on erythroid and granulomonocytic differentiation of U2AF1S34F MDS hemato-
poietic progenitors. Late erythroid (CD71–CD235a+) cell population in transduced erythroblasts expressing H2AFY isoform 1.1 (H) or the STRAP long isoform 
(I), measured by flow cytometry on day 14 of culture compared with the EV control. (J) Monocytic (CD14+CD15–) and (K) granulocytic (CD14–CD15+) cell 
populations in transduced granulomonocytic cells expressing H2AFY isoform 1.1 were measured by flow cytometry on day 20 of culture compared with the 
EV control. In panels A and B, quantification of altered splicing events in gel was performed using ImageJ. Bar graph results in A and B were obtained from 
4 technical replicates. Data represent the mean ± SEM. P values in panels A–E were calculated by an unpaired, 2-tailed t test. P values in panels H–K were 
calculated by a paired, 2-tailed t test. *P < 0.05, **P < 0.01, and ***P < 0.001.
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showed increased apoptosis (Supplemental Figure 7C) and no signif-
icant cell-cycle changes (Supplemental Figure 7D). Our data indicate 
that H2AFY plays an important role in human hematopoiesis and that 
decreased expression of the isoform 1.1 expression associated with 
aberrant splicing of H2AFY in the presence of U2AF1S34F impairs both 
erythroid and granulomonocytic differentiation.
In this study, we showed that U2AF1S34F induced skipping 
of exon 2 of the STRAP gene preferentially in erythroid colo-
nies compared with granulomonocytic colonies (Figure 4, D and 
E). This splicing alteration gives rise to a premature stop codon, 
which is expected to lead to degradation of the mRNA tran-
scripts by nonsense-mediated decay. Indeed, we found decreased 
expression of STRAP mRNA in U2AF1S34F erythroid cells by 
qRT-PCR (Supplemental Figure 7E). In contrast, downregulation 
of STRAP mRNA was not observed in U2AF1S34F granulomonocyt-
ic cells (Supplemental Figure 7F). To investigate the effects of this 
lineage-specific splicing alteration on hematopoiesis, shRNAs were 
used to knock down STRAP expression in bone marrow CD34+ pro-
genitor cells differentiated toward the erythroid lineage (Figure 
6A). One shRNA (sh66) resulted in approximately 50% knockdown 
(Figure 6A), a level similar to that observed in U2AF1S34F erythroid 
cells (Supplemental Figure 7E). Erythroblasts with STRAP knock-
down showed G1 cell-cycle arrest compared with the scramble con-
trol (Figure 6B). Similar to U2AF1S34F erythroblasts, erythroblasts 
with STRAP knockdown showed defective hemoglobinization on 
day 14 (Figure 6C) and a significant decrease in the CD71–CD235a+ 
late erythroid cell population on day 14 of culture compared with the 
scramble control (Figure 6D). Transduced progenitors with STRAP 
knockdown also produced a significantly lower number of BFU-E 
colonies than did the scramble control (Figure 6E). These results 
support a critical role for STRAP in human erythroid differentiation.
Inclusion of exon 2 of ITGB3BP was associated with the pres-
ence of U2AF1S34F in granulomonocytic cells only in our study. To 
investigate the effect of this splicing alteration on hematopoiesis, 
the isoform of ITGB3BP including exon 2 was overexpressed in 
bone marrow CD34+ progenitor cells differentiated toward the 
granulomonocytic lineage (Figure 6F). However, granulomono-
cytic cells with ITGB3BP overexpression showed no significant 
difference in cell-cycle pattern (Figure 6G) or apoptosis (Sup-
plemental Figure 7G). We observed only a small reduction in the 
CD14+ monocytic cell population (Figure 6, H and J) and no differ-
ence in the CD15+ granulocytic cell population (Figure 6, I and J) in 
cells with ITGB3BP overexpression compared with the EV control. 
Morphological examination confirmed that no skewing in granu-
lomonocytic differentiation occurred in cells with ITGB3BP over-
expression (Figure 6K). These results indicate that overexpression 
of the isoform of ITGB3BP including exon 2, while associated with 
the presence of U2AF1S34F in granulomonocytic cells, does not sig-
nificantly impact human granulomonocytic differentiation.
Overexpression of U2AF1WT in U2AF1S34F–mutant MDS hema-
topoietic progenitors. To investigate whether overexpression of 
U2AF1WT rescues the aberrant hematopoiesis associated with 
U2AF1S34F in MDS, we overexpressed U2AF1WT in U2AF1S34F MDS 
hematopoietic progenitors by retroviral transduction. Overex-
pression of U2AF1WT in transduced U2AF1S34F MDS erythroid 
and granulomonocytic cells was confirmed on day 11 by Western 
blotting (Supplemental Figure 8A). However, we observed no sig-
(Supplemental Figures 5 and 6). Our data show that U2AF1S34F dif-
ferentially alters splicing of target genes in a lineage-specifc man-
ner in the erythroid and granulomonocytic lineages, supporting 
the hypothesis that the same splicing factor gene mutation can 
drive aberrant splicing of distinct genes in different cell populations.
Park et al. recently reported selection of a distal cleavage and 
polyadenylation (CP) site in the autophagy-related factor 7 (Atg7) 
pre-mRNA in association with the presence of the U2AF1S34F muta-
tion (32). This results in a decrease in ATG7 levels that leads to defec-
tive autophagy, making cells more prone to secondary mutations (32). 
We performed qRT-PCR to evaluate selection of the distal CP site of 
ATG7 (32) in U2AF1S34F erythroid and granulomonocytic colonies in 
our study. We did not observe increased usage of the distal CP site 
of ATG7 in U2AF1S34F granulomonocytic cells (distal/proximal CP site 
usage ratios of 1.03 and 0.98 in U2AF1S34F and U2AF1WT, respectively, 
compared with the EV control), however this represents a different 
cell population from that studied by Park et al. (32). The expression of 
ATG7 was too low for assessment in U2AF1S34F erythroid cells.
Functional effects of splicing aberrations associated with 
U2AF1S34F. We performed functional studies to determine the 
impact of the splicing abnormalities identified in H2AFY, STRAP, 
and ITGB3BP on human erythroid and/or granulomonocytic cell 
growth and differentiation.
Usage of the mutually exclusive exons 6a and 6b in the H2AFY 
gene gives rise to the 2 transcript isoforms 1.2 and 1.1, respective-
ly. Our RNA-seq data showed that U2AF1S34F was associated with 
altered pre-mRNA splicing of H2AFY, with decreased usage of exon 
6b resulting in a decrease in the expression levels of the isoform 1.1 
of this gene in both erythroid and granulomonocytic colonies. To 
examine the effects of reduced expression of the H2AFY isoform 1.1 
on human hematopoiesis, we designed shRNAs to specifically knock 
down the H2AFY isoform 1.1 (Figure 5, A and G), without affect-
ing the expression of the H2AFY isoform 1.2 (Figure 5, B and H) in 
bone marrow CD34+ progenitor cells. Transduced progenitor cells 
were cultured under erythroid and granulomonocytic conditions as 
previously described (27, 28). Erythroblasts with H2AFY isoform 1.1 
knockdown showed increased apoptosis (Supplemental Figure 7A) 
and G1 cell-cycle arrest (Supplemental Figure 7B). Similar to eryth-
roblasts expressing U2AF1S34F, erythroid cells with H2AFY isoform 
1.1 knockdown showed defective hemoglobinization on day 14 of 
culture compared with the scramble shRNA control (Figure 5C). Fur-
thermore, erythroblasts with H2AFY isoform 1.1 knockdown showed 
a significant decrease in the CD71+CD235a+ intermediate erythroid 
cell population on day 11 (Figure 5D), followed by a decrease in the 
CD71–CD235a+ late erythroid cell population on day 14 compared 
with the scramble control (Figure 5E). Transduced progenitors with 
H2AFY isoform 1.1 knockdown also produced a significantly lower 
number of BFU-E colonies than did the scramble control (Figure 5F). 
Granulomonocytic cells with H2AFY isoform 1.1 knockdown (Figure 
5, G and H) showed a significant increase in the CD14+CD15+ cell pop-
ulation compared with the scramble control (Figure 5I), and H2AFY 
isoform 1.1 knockdown exerted a skewing effect on granulomono-
cytic differentiation toward granulocytes (Figure 5J). Morphological 
examination confirmed the expansion of granulocyte eosinophils 
in granulomonocytic cultures with H2AFY isoform 1.1 knockdown 
compared with the scramble control on day 20 of culture (Figure 5K). 
Granulomonocytic cells with knockdown of the H2AFY isoform 1.1 
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Discussion
Patients with MDS suffer from refractory anemia, which is a 
defining feature of this disorder (1, 33). In our study, we demon-
strated that expression of U2AF1S34F in human hematopoietic pro-
genitors results in impaired erythroid differentiation as a result of 
poor hemoglobinization and reduced growth of erythroid progen-
itors. These in vitro results therefore show that the presence of 
the U2AF1 mutation impairs human erythropoiesis and indicate 
that this mutation may play an important role in the development 
of anemia in MDS. Interestingly, it has been reported that U2AF1 
mutations in patients with MDS are associated with lower hemo-
globin levels when compared with patients with WT U2AF1 (34).
MDS have a defective maturation program of myeloid pro-
genitors (1, 4). We showed that expression of U2AF1S34F in human 
hematopoietic progenitors results in the skewing of granulomono-
cytic differentiation toward granulocytes (specifically eosinophils). 
Similar phenotypes were also observed in the bone marrow com-
partment of an U2AF1S34F-transgenic mouse model (26): U2AF1S34F 
mice showed a significant decrease in monocytes, together with 
a significant increase in granulocyte neutrophils in the bone mar-
row, compared with control mice (26). Interestingly, eosinophilia 
has been reported in some patients with de novo MDS (35, 36). Our 
study demonstrates a link between U2AF1S34F and skewed granulo-
monocytic differentiation in human hematopoiesis.
We found that expression of U2AF1S34F has a suppressive effect 
on cell growth in transduced erythroid and granulomonocytic 
cells. Likewise, introduction of the U2AF1S34F mutation into can-
cer cell lines results in impaired cell growth (6), and this is also 
observed with other splicing factor gene mutations (37). How 
splicing factor mutations confer a clonal growth advantage in 
myeloid malignancies is not yet fully understood.
The phenotypic changes produced by U2AF1S34F likely reflect 
differences in the downstream target genes and pathways affected 
in each lineage and in the type of aberrant splicing events associat-
ed with the presence of U2AF1S34F. In support of this, we identified 
aberrant splicing events in many downstream target genes specif-
ic to U2AF1S34F erythroid and granulomonocytic colonies, using 
RNA-seq. Our RNA-seq data should be interpreted with the cave-
ats that U2AF1S34F expression levels (at a variant allele frequency 
[VAF] of >80%) in U2AF1S34F-transduced cells is higher than the 
level expected in MDS patients with heterozygous U2AF1 muta-
tions (i.e., 50% VAF) and that the U2AF1S34F erythroid and granu-
lomonocytic colonies analyzed contain some heterogeneity in the 
stage of differentiation (but they are nevertheless all fully commit-
ted toward either the myeloid or erythroid path). We suggest that 
the aberrantly spliced target genes may play a role in the aberrant 
growth and differentiation of cells of the erythroid and granulo-
monocytic lineages expressing this mutation.
Other studies have shown that aberrant cassette exon splicing 
is a common consequence of U2AF1 mutations (18, 23, 25), and we 
found that cassette exons were the most common type of aberrant 
splicing event induced by U2AF1S34F in both erythroid and granu-
lomonocytic colonies. Interestingly, we observed a significantly 
higher number of misregulated cassette exon events in granulo-
monocytic U2AF1S34F colonies compared with erythroid U2AF1S34F 
colonies in our study (Figure 3, B and C). Notably, the UAG 3′ splice 
site signature of cassette exons that are more skipped is similar to 
nificant improvement in erythroid or granulomonocytic differ-
entiation in transduced U2AF1S34F MDS cells with U2AF1WT over-
expression compared with the EV control (Supplemental Figure 
8, B–D). Importantly, we found that overexpression of U2AF1WT 
did not correct the aberrant splicing activity of H2AFY or STRAP 
in U2AF1S34F MDS cells (Supplemental Figure 8, E–G), consistent 
with the gain-of-function/neomorphic role of U2AF1S34F.
Overexpression of H2AFY isoform 1.1 and the STRAP long iso-
form rescues erythroid differentiation defects in U2AF1S34F MDS cells. 
In order to determine whether modulation of H2AFY and STRAP 
isoform ratios can rescue the aberrant hematopoiesis associat-
ed with U2AF1S34F, we performed rescue experiments in which 
H2AFY isoform 1.1 or the STRAP long isoform were overexpressed 
in U2AF1S34F MDS hematopoietic progenitors.
First, we evaluated whether aberrant splicing of H2AFY and 
STRAP occurs in the erythroid and granulomonocytic cells differen-
tiated from U2AF1S34F MDS hematopoietic progenitors. We differ-
entiated U2AF1S34F MDS CD34+ hematopoietic progenitor cells into 
erythroid and granulomonocytic cells as previously described (27, 
28). Consistent with our RNA-seq results of U2AF1S34F-transduced 
erythroid and granulomonocytic colonies (Figure 4), U2AF1S34F 
MDS erythroid and granulomonocytic cells harvested on day 7 
showed a significant reduction in H2AFY isoform 1.1 compared with 
healthy controls (Figure 7A). U2AF1S34F MDS erythroid cells harvest-
ed on day 7 also demonstrated a significant increase in the STRAP 
short isoform compared with healthy controls (Figure 7B). We did 
not observe aberrant splicing of STRAP in U2AF1S34F MDS granulo-
monocytic cells harvested on day 7, further confirming our results 
of a lineage-specific effect of U2AF1S34F mutation on this target gene 
(Figure 7B). Moreover, U2AF1S34F MDS hematopoietic progenitors 
showed impaired erythroid differentiation on day 14 (Figure 7C) 
and skewed granulomonocytic differentiation toward granulocytes 
on day 20 (Figure 7, D and E) compared with healthy control cells.
Next, we overexpressed H2AFY isoform 1.1 or the STRAP long 
isoform in U2AF1S34F MDS hematopoietic progenitors by lentivi-
ral transduction. Overexpression of H2AFY isoform 1.1 in trans-
duced U2AF1S34F MDS erythroid and granulomonocytic cells was 
confirmed by RT-PCR compared with the EV control (Figure 7F). 
We also confirmed overexpression of the STRAP long isoform in 
transduced U2AF1S34F MDS erythroblasts by RT-PCR compared 
with the EV control (Figure 7G). The percentage of CD71–CD235a+ 
erythroblasts on day 14 ranged from 14.5% to 17.2% in healthy con-
trols (Figure 7C). Overexpression of H2AFY isoform 1.1 resulted in 
an increase in late CD71–CD235a+ erythroblasts (to 5.7% to 15.5%, 
i.e., a 1.54- to 1.85-fold increase) on day 14 in the three U2AF1S34F 
MDS patients, with a trend toward significance compared with 
the EV control (Figure 7H). Overexpression of the STRAP long 
isoform resulted in a significant increase in late CD71–CD235a+ 
erythroblasts (to 6.5% to 14.1%, i.e., a 1.59- to 2.53-fold increase) 
on day 14 in the three U2AF1S34F MDS patients compared with the 
EV control (Figure 7I). However, we observed no change in mono-
cytic or granulocytic cell differentiation in transduced U2AF1S34F 
MDS granulomonocytic cells with overexpression of H2AFY iso-
form 1.1 (Figure 7, J and K).
These results indicate that overexpression of H2AFY isoform 
1.1 and the STRAP long isoform rescues erythroid differentiation 
defects in U2AF1S34F MDS cells.
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Knockdown of the H2AFY isoform 1.1 in granulomonocytic cells 
resulted in a skewed differentiation toward the granulocyte pop-
ulation, specifically eosinophils, closely mirroring the effects of 
U2AF1S34F on granulomonocytic differentiation. Our functional 
data therefore indicate that changes in the abundance of H2AFY 
isoform 1.1 also play a role in the differentiation of granulomono-
cytic cells. Thus, reduced expression of H2AFY isoform 1.1 reca-
pitulated the phenotypes associated with expression of U2AF1S34F 
in erythroid and/or granulomonocytic cells, suggesting a causal 
link. Importantly, we showed that the aberrant splicing event in 
the H2AFY gene that we identified in U2AF1S34F erythroid and 
granulomonocytic colonies also occurs in purified bone marrow 
CD34+ cells from patients with U2AF1S34F MDS.
We have shown that U2AF1S34F differentially alters mRNA 
splicing of many target genes in a lineage-specific manner in 
erythroid and granulomonocytic colonies. For example, splicing 
alterations in STRAP and SMARCA5 preferentially occur in the 
erythroid lineage, while splicing alterations in ITGB3BP and ATR 
preferentially occur in the granulomonocytic lineage. STRAP is 
a serine/threonine kinase receptor–associated protein that plays 
a role in the cellular distribution of the survival of motor neu-
rons (SMN) complex, important in the assembly of snRNPs (47). 
Deregulated expression of STRAP is associated with other human 
cancers, including those of the lung, colon, and breast (48, 49).
In this study, we showed that U2AF1S34F induced aberrant splic-
ing of STRAP, leading to downregulation of this gene in erythroid 
cells only, and that knockdown of STRAP in human erythroblasts 
results in impaired erythroid differentiation. These results support 
a critical role for STRAP in human erythroid differentiation and 
suggest that aberrant splicing of STRAP leads to impaired erythro-
poiesis in association with U2AF1S34F. Interestingly, STRAP acts as 
a negative regulator of the TGF-β signaling pathway through inter-
action with Smad7 (50), and TGF-β signaling exerts an inhibitory 
effect on erythroid cell growth during differentiation (51).
We have thus identified H2AFY and STRAP as key downstream 
target genes of U2AF1S34F in human cells of the myeloid lineage, with 
aberrantly spliced H2AFY and STRAP both being critical effectors 
of impaired erythropoiesis and aberrantly spliced H2AFY also being 
a critical effector of aberrant granulomonocytic cell differentiation. 
While aberrant splicing of these target genes leads to impaired dif-
ferentiation of progenitor cells, in the stem cell compartment this 
might be predicted to result in a negative selection pressure on stem 
cells. We suggest that these splicing abnormalities play a role in the 
development of cytopenias that are hallmarks of MDS.
Importantly, we provide the first evidence, to our knowledge, 
that isoform modulation of the U2AF1S34F target genes H2AFY 
and STRAP ameliorates the erythroid differentiation defect in 
U2AF1S34F MDS cells. Overexpression of H2AFY isoform 1.1 and 
the STRAP long isoform resulted in an improvement in erythroid 
differentiation, raising the possibility of using splicing modula-
tors therapeutically. Approaches that involve the use of antisense/
splice site–switching oligonucleotides (ASOs/SSOs) alter the bal-
ance between mRNA isoforms, with the aim of restoring normal 
splicing or preferentially expressing specific isoforms (52). ASOs/
SSOs have shown efficacy in splicing modulation in in vivo mouse 
studies and are being used in clinical trials for the treatment of spi-
nal muscular atrophy and Duchenne muscular dystrophy (53). The 
the optimal RNA-binding sequence for the U2AF heterodimer (16), 
strongly supporting the idea that missplicing of this group of exons is 
a direct consequence of U2AF1 mutation. The fact that these exons 
have significantly weaker 5′ splice sites suggests that their inclu-
sion may be dependent on optimal interaction of U2AF1 at their 3′ 
splice sites, explaining their sensitivity to U2AF1 mutation. Splicing 
of many exons is dependent not only on the strength of their con-
sensus splice site sequences, but also on auxiliary elements such as 
exonic splicing enhancers (ESEs) (38). There are numerous classes 
of ESEs that bind different splicing activators often expressed with 
different cell-type specificity. Lineage- and exon-specific skipping 
might therefore occur in the absence of the optimal U2AF1–3′ splice 
site interaction (U2AF1S34F), combined with a cell type–specific lack 
of the ESE-binding activator protein. In contrast, the molecular 
basis of the increased inclusion of other cassette exons in response 
to U2AF1S34F is unclear, although it was observed previously that 
some exons are upregulated upon knockdown of U2AF1 (39).
In our study, we found that 20 genes were aberrantly spliced 
in cells of both erythroid and granulomonocytic lineages and thus 
represent common downstream targets of U2AF1S34F that may play 
a role in the phenotypic changes observed in both lineages. H2AFY 
was one of these genes, showing a mutually exclusive exon splicing 
event in both lineages. H2AFY encodes the core histone macro- 
H2A1, which is involved in X chromosome inactivation (40) and 
is required for both transcriptional silencing and induction (41). 
Intriguingly, loss of X chromosome inactivation results in MDS-like 
phenotypes in mice (42). Alternative splicing in H2AFY has been 
shown to generate 2 functionally different isoforms (43). A role 
for macro histone variants in repressing gene expression during 
cell differentiation has been shown in embryonic and adult stem 
cells, and in pluripotent cells, in which these variants are recruit-
ed to the regulatory regions of genes that retain or gain H3K27me3 
during differentiation (44). H2AFY isoform 1.1 has been shown to 
be generally expressed in more differentiated cells (45). We found 
a reduction in the expression of isoform 1.1 of H2AFY associated 
with U2AF1S34F in transduced erythroid cells. Critically, we then 
showed that knockdown of H2AFY isoform 1.1 in human erythro-
blasts resulted in impaired erythroid differentiation. Interestingly, 
isoform changes in H2AFY have been shown to play a role in nor-
mal erythroid differentiation. Pimentel et al. demonstrated that the 
relative expression of mutually exclusive exons is reversed almost 
completely between proerythroblasts (mostly expressing isoform 
1.2) and orthochromatic erythroblasts (mostly expressing isoform 
1.1), indicating that the alternative splicing switch from isoform 1.2 
to isoform 1.1 of H2AFY occurs during normal late erythroid dif-
ferentiation (46). Our data show that aberrant splicing of H2AFY 
associated with the presence of U2AF1S34F leads to a reduction 
in the expression of isoform 1.1 of this gene. Here, isoform 1.1 is 
the minor isoform (compared with isoform 1.2), and, strikingly a 
small reduction in this isoform resulted in a marked impairment 
of erythropoiesis. We provide evidence that this imbalance of the 
two H2AFY isoforms prevents erythroblasts from undergoing ter-
minal differentiation. We suggest that aberrant splicing of H2AFY 
leads to impaired erythropoiesis and may play a role in the anemia 
observed in MDS patients with U2AF1 mutation.
We also found a reduction in the expression of isoform 1.1 
of H2AFY associated with U2AF1S34F in granulomonocytic cells. 
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Thermo Fisher Scientific) (0.75 mg/ml and 1.0 mg/ml for erythroid 
and granulomonocytic cells, respectively).
Lentiviral constructs containing shRNAs targeting H2AFY iso-
form 1.1 were obtained by cloning oligonucleotides (shRNA sequences 
are described in Supplemental Table 1) into the pLKO.1-puro vector 
(Sigma-Aldrich). shRNAs targeting STRAP in the pLKO.1-puro vector 
(TRCN0000060465 and TRCN0000060466) were obtained from 
Sigma Mission. The lentiviral construct containing ITGB3BP isoform 
1, H2AFY isoform 1.1, or STRAP long isoform cDNA in the pReceiver- 
Lv156 vector was obtained from GeneCopoeia. The procedures of 
lentivirus production and transduction were the same as those used 
for retroviruses, except MISSION lentiviral packaging mix (Sigma- 
Aldrich) was used for transfection with vector plasmids into HEK293T 
cells. The selection of transduced cells was performed in medium con-
taining 0.65 μg/ml puromycin (Thermo Fisher Scientific).
Flow cytometry. To evaluate erythroid differentiation, cells were 
incubated for 30 minutes on ice with anti-CD36-PE (clone 5-271; 
BioLegend), anti-CD71-FITC (clone OKT9; eBioscience), and anti–
CD235a-APC (clone HIR2; BioLegend) antibodies before staining with 
0.5 μg/ml DAPI (Sigma-Aldrich). To evaluate granulomonocytic differ-
entiation, cells were first incubated for 30 minutes on ice with Fixable 
Viability Dye eFluor 780 (eBioscience). After washing with PBS, cells 
were incubated on ice for 30 minutes with anti-CD11b Brilliant Vio-
let 421 (clone ICRF44; BioLegend), anti–CD14-FITC (clone RMO52; 
Beckman Coulter), and anti–CD15-APC (clone W6D3; BioLegend) 
antibodies. To perform apoptosis assays, cells resuspended in annex-
in V–binding buffer (BioLegend) were stained with annexin V-FITC 
antibody (BioLegend) for 20 minutes in the dark according to the man-
ufacturer’s instructions. Propidium iodide (1 μg/ml) was added to the 
cells before analysis. To perform cell-cycle analysis, cells were fixed 
with ice-cold absolute ethanol for 30 minutes before incubation with 
40 μg/ml propidium iodide and 10 μg/ml RNase A for 1 hour at 37°C. 
Flow cytometry was performed on a BD LSRII (BD Biosciences), and 
the data were analyzed using FlowJo software, version 7.6.4.
Colony-forming cell assays. Colony-forming cell assays were per-
formed using MethoCult H4434 and H4534 methylcellulose (STEM-
CELL Technologies) according to the manufacturer’s instructions. 
Transduced cells (3,000 cells) were grown in methylcellulose con-
taining 1.0 mg/ml Geneticin (Thermo Fisher Scientific). The number 
and morphology of the colonies were analyzed after 14 days in culture.
RNA-seq. Individual BFU-E colonies (n = 3 each for U2AF1S34F, 
U2AF1WT, and EV) and CFU-G/M colonies (n = 3 each for U2AF1S34F, 
U2AF1WT, and EV) were first harvested for RNA extraction using TRIzol 
reagent (Thermo Fisher Scientific) according to the manufacturer’s 
instructions. RNA was also extracted from bone marrow CD34+ cells 
enriched from mononuclear cells obtained from 6 MDS patients and 
5 healthy controls using CD34 MicroBeads (Miltenyi Biotec). Two 
patients with MDS had U2AF1S34F mutations, whereas 4 patients had 
no known mutations in splicing factor genes (SF3B1, SRSF2, U2AF1, 
or ZRSR2) as determined by targeted next-generation sequencing data 
from a previous study (5). Linear acrylamide (20 μg) (Thermo Fish-
er Scientific) was used as the RNA coprecipitant. Total RNA was then 
DNase treated (Invitrogen, Thermo Fisher Scientific), purified using XP 
beads (Beckman Coulter), and amplified (100  ng) for 12 cycles using 
the SMART mRNA Amplification Kit (Clontech) according to the man-
ufacturer’s instructions. Library preparation was performed using the 
NEBNext DNA Library Prep Kit (New England BioLabs) according to 
use of splicing modulators may have efficacy in the treatment of 
myeloid malignancies with U2AF1 mutations.
We observed no change in granulomonocytic differentiation 
in transduced U2AF1S34F MDS cells overexpressing H2AFY iso-
form 1.1, indicating that the correction of a single isoform change 
of H2AFY may not be sufficient to fully rescue the defect in granu-
lomonocytic differentiation in patients’ cells and that modulation 
of aberrant splicing of multiple target genes may be required.
We also overexpressed U2AF1WT in U2AF1S34F MDS hemato-
poietic progenitors. However, we observed no significant differ-
ence in erythroid or granulomonocytic differentiation between 
transduced U2AF1S34F MDS cells with U2AF1WT overexpression 
and EV controls. U2AF1 mutations in myeloid malignancies are 
considered gain-of-function/neomorphic mutations. As U2AF1S34F 
is still expressed in MDS cells, it would continue to cause aberrant 
splicing of its target genes, and this may therefore explain why 
overexpression of U2AF1WT does not rescue the functional defects 
observed in U2AF1S34F MDS cells. Alternatively, the U2AF1 muta-
tion may exert its effect mostly early in MDS disease develop-
ment, and the rescue is less effective at a later stage.
Our results demonstrate that U2AF1S34F shows lineage speci-
ficity in altering pre-mRNA splicing of downstream target genes, 
resulting in different phenotypes in different myeloid lineages. 
These findings shed light on the events underlying the phenotypic 
heterogeneity in MDS. It will be important to determine whether 
other splicing factor genes commonly mutated in MDS, namely 
SF3B1, SRSF2, and ZRSR2, also exhibit lineage specificity in alter-
ing the splicing of target genes to drive different phenotypes in dif-
ferent hematopoietic lineages.
The identification of key target genes of the common spliceo-
some mutations in cells of the erythroid and granulomonocytic 
lineages is crucial for understanding how the mutations contribute 
to MDS pathophysiology and for designing new targeted therapeu-
tic strategies. It is now recognized that splicing factor gene muta-
tions are common in many cancers, and we believe that our work 
has broad implications for the understanding of how these muta-
tions result in cell type–specific phenotypes in other malignancies.
Methods
Cell culture. Bone marrow CD34+ cells from healthy controls (Lonza) 
and from U2AF1S34F MDS patients were cultured for 14 and 20 days 
to generate erythroblasts and granulomonocytic cells, respectively, 
as previously described (27, 28). All cytokines were obtained from 
Miltenyi Biotec, except for erythropoietin, which was obtained from 
Roche. Medium was replenished every second day to maintain the 
same cell concentration.
Viral transduction. Retroviral pGCDNsam-IRES-EGFP plas-
mids containing U2AF1S34F and U2AF1WT cDNA were used following 
replacement of the EGFP sequence with neomycin to impart G418 
resistance (6). To obtain high-titer retrovirus stock, vector plasmids 
were cotransfected with vesicular stomatitis virus glycoprotein enve-
lope and Gag/Pol plasmids using Lipofectamine 2000 (Life Tech-
nologies, Thermo Fisher Scientific) into HEK293T cells as previously 
described (6). Spinoculation was performed in the presence of 8 μg/ml 
polybrene (Sigma-Aldrich) at 800 ×g and 32°C for 2 hours. After over-
night incubation with retroviruses, the selection of transduced cells 
was performed in medium containing Geneticin (Life Technologies, 
The Journal of Clinical Investigation   R E S E A R C H  A R T I C L E
2 2 1 9jci.org   Volume 127   Number 6   June 2017
as well as sequences corresponding to the 5′splice site of the upstream 
exon and 3′ splice site of the downstream exon. For the erythroid 
U2AF1S34F versus U2AF1WT cells, we obtained 71 exons that were more 
skipped and 108 exons that were more included. For the granulomono-
cytic U2AF1S34F versus U2AF1WT cells, we obtained 190 more skipped 
exons and 157 more included exons. As control data sets, we used SE 
exons expressed in the erythroid and granulomonocytic cells, but not 
regulated (FDR >0.05 and IncLevelDifference values of –0.05 to 0.05). 
Human sequences were retrieved from the UCSC Genome Browser 
(hg19, February 2009) using R and the following Bioconductor pack-
ages: Genomic Ranges, Genomic Features, biomaRt, and BSgenome. 
Hsapiens.UCSC.hg19 (63–65). Graphical outputs were generated with 
the CRAN package ggplot2. For box plots, the whiskers represent 1.5 times 
the interquartile range. Statistical analysis comparing sequences proper-
ties between data sets was done using a Kruskal-Wallis test, followed by 
2-sided Mann-Whitney U tests with Bonferroni’s correction. Sequence 
logos were produced using WebLogo (http://weblogo.berkeley.edu/
logo.cgi) (66). Splice site strength was calculated using MaxEntScan 
software (http://genes.mit.edu/burgelab/maxent/Xmaxentscan_
scoreseq_acc.html) (67). Sequences were extracted following the devel-
oper’s instructions for 3′ splice sites and 5′splice sites. MaxEnt scores 
were plotted using ggplot2 (http://github.com/hadley/ggplot2). Branch 
point scores and the distance the between branch point and the 3′splice 
site was obtained using SVM-BPfinder (http://regulatorygenomics. 
upf.edu/Software/SVM_BP/) (68). Data were filtered by restricting the 
predicted branch point to being located between the 3′splice site and 12 
bp upstream of the AG-dinucleotide exclusion zone (AGEZ) and select-
ing the top svm_scr scoring for each event.
Statistics. The significance of the comparisons between cells trans-
duced with U2AF1S34F, U2AF1WT, or EV was determined by repeated- 
measures 1-way ANOVA with Tukey’s post-hoc tests. The measure-
ments of cell growth over time for cells transduced with U2AF1S34F, 
U2AF1WT, or EV were compared using 2-way ANOVA and Bonferroni’s 
post tests. The significance of comparisons between 2 groups was 
determined by paired or unpaired 2-tailed t tests as indicated. Com-
parisons of each type of aberrantly spliced events identified by rMATS 
between erythroid and granulomyocytic conditions were determined 
by Fisher’s exact test with Bonferroni’s correction. P values of less than 
0.05 were considered statistically significant.
Study approval. The MDS patient samples used in this study were 
obtained with written informed consent under approval by the IRBs 
of the Karolinska Institutet and the IRCSS Policlinico San Matteo.
Information regarding qRT-PCR, Western blotting, cell growth 
assays, May-Grünwald–Giemsa staining, pyrosequencing, SYBR 
Green qRT-PCR, and cloning and Sanger sequencing can be found 
in the Supplemental Methods.
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